On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Abstract
Cost-effectiveness analysis (CEA) aims to evaluate the additional amount of health that an intervention provides to patients and how much more it costs compared to alternatives. While many health systems have used CEA for decades to inform coverage or reimbursement policies, in the US, it is now a contested political issue. One group of critics contend that CEA may be used to identify patient subgroups who are cost-ineffective to treat, resulting in treatment denials and discrimination. Recently, new perspectives on CEA argue that subgroups should be included to identify opportunities to advance health equity. Given these conflicting claims, this paper considers when subgroup analysis is justifiable and how results should be implemented.
This will be a hybrid seminar in the Richard Doll Building Lecture Theatre or on Zoom (medsci.zoom.us/j/92573286349).
